Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Sold by Asset Management One Co. Ltd.

Asset Management One Co. Ltd. trimmed its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 6.2% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 428,837 shares of the company's stock after selling 28,534 shares during the period. Asset Management One Co. Ltd.'s holdings in Teva Pharmaceutical Industries were worth $6,591,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the stock. Thrivent Financial for Lutherans boosted its position in shares of Teva Pharmaceutical Industries by 0.3% in the fourth quarter. Thrivent Financial for Lutherans now owns 225,210 shares of the company's stock worth $4,964,000 after purchasing an additional 699 shares during the period. Bfsg LLC grew its stake in shares of Teva Pharmaceutical Industries by 7.8% in the 1st quarter. Bfsg LLC now owns 10,960 shares of the company's stock worth $168,000 after buying an additional 790 shares in the last quarter. Townsquare Capital LLC grew its stake in shares of Teva Pharmaceutical Industries by 2.1% in the 4th quarter. Townsquare Capital LLC now owns 40,162 shares of the company's stock worth $885,000 after buying an additional 812 shares in the last quarter. Metis Global Partners LLC raised its stake in shares of Teva Pharmaceutical Industries by 6.7% in the fourth quarter. Metis Global Partners LLC now owns 13,697 shares of the company's stock valued at $302,000 after acquiring an additional 860 shares during the period. Finally, Quadrant Capital Group LLC raised its stake in shares of Teva Pharmaceutical Industries by 27.7% in the fourth quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company's stock valued at $96,000 after acquiring an additional 949 shares during the period. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE:TEVA traded up $0.20 during trading on Friday, hitting $16.76. 8,942,158 shares of the stock traded hands, compared to its average volume of 10,289,327. The company has a market cap of $19.22 billion, a price-to-earnings ratio of -14.57, a P/E/G ratio of 0.86 and a beta of 0.60. The company has a fifty day moving average price of $16.72 and a two-hundred day moving average price of $17.39. The company has a quick ratio of 0.74, a current ratio of 1.03 and a debt-to-equity ratio of 2.59. Teva Pharmaceutical Industries Ltd. has a 52-week low of $12.47 and a 52-week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, topping the consensus estimate of $0.47 by $0.05. Teva Pharmaceutical Industries had a negative net margin of 7.74% and a positive return on equity of 45.44%. The company had revenue of $3.89 billion during the quarter, compared to analyst estimates of $3.99 billion. During the same quarter in the previous year, the firm earned $0.48 EPS. The firm's revenue was up 1.9% compared to the same quarter last year. As a group, equities analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Analysts Set New Price Targets

TEVA has been the topic of several recent analyst reports. Truist Financial initiated coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They issued a "buy" rating and a $25.00 price target on the stock. Hsbc Global Res upgraded shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a report on Monday, April 28th. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. UBS Group lowered their target price on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating for the company in a research note on Thursday. Finally, The Goldman Sachs Group initiated coverage on shares of Teva Pharmaceutical Industries in a research note on Friday, June 6th. They set a "buy" rating and a $24.00 price objective for the company. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of "Buy" and a consensus target price of $24.13.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, EVP Matthew Shields sold 6,206 shares of the business's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total value of $105,626.12. Following the transaction, the executive vice president now directly owns 9,989 shares in the company, valued at $170,012.78. The trade was a 38.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 0.49% of the stock is currently owned by corporate insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.